1985 |
Cavenee, Webster |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Molecular Genetics of a Familial Human Eye Tumor @ University of Cincinnati
Inheritance of a mutation at the Rb-1 locus, which has been mapped to band q14 of human chromosome 13, results in predisposition to retinoblastoma. Cloned DNA segments which have homology to arbitrary loci on human chromosome 13 and which reveal polymorphic restriction endonuclease recognition sequences will be isolated. These segments will be used as molecular probes in a comparison of constitutional and tumor genotypes in order to look for somatic genetic events that might occur during tumorigenesis. Similarly, constitutional and tumor genotypes of patients affected by secondary malignancies will be determined and the frequency with which heterozygosity is lost in these tumors will be ascertained. Loci homologous to the cloned DNA segments will be physically mapped through the use of various somatic cell hybrids and by in situ hybridization to metaphase chromosomes. This physical map will be compared to a genetic linkage map which will be obtained by segregation analysis in human pedigrees. These studies should provide basic information about chromosomal mechanisms involved in human tumor formation in vivo and about the frequency of recombination between many loci on this autosome. If these mechanisms are determined to be involved in other tumor types, a general methodology for mapping genes which predispose to tumorigenesis will be obtained, facilitating their identification, isolation and molecular analysis. Additionally, genetic markers should be identified which will be useful predictive tools in genetic counseling of parents afflicted with retinoblastoma.
|
0.906 |
1985 |
Cavenee, Webster |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Recombinant Dna Technology to Pediatric Cancer @ University of Cincinnati
The purpose of this research is to evaluate the applicability of recombinant DNA technology and molecular genetic analysis to the clinical diagnosis and detection of cancer in children. The utilization of cloned human DNA segments in defining unique molecular changes in the arrangement or number of loci which occur in malignant cells as compared to normal cells from the same patients may serve as an exquisitely sensitive measure of the type of existing cancer and its expected prognosis. The establishment of a large resource panel of paired normal and neoplastic samples will be of primary importance. The interaction of pediatric oncologists and pathologists based in hospitals which are members of the Children's Cancer Study Group (CCSG) will allow access to several hundred new tumors a year. Each of the pathologic, clinical and laboratory evaluations of these cases are routinely reviewed by the CCSG using standardized criteria and protocols. Thus, over a thousand well-defined primary samples will be available for analysis. Additional materials from these samples will be generated by Epstein-Barr virus transformation of peripheral blood lymphocytes from each case and by passaging most solid tumors in immunodeficient mice, thereby assuring continued viability of this resource. Paired normal and neoplastic sample sets will be processed for DNA isolation and analyzed for two different, but complementary, molecular features. Hybridization of these DNA samples with cellular and viral oncogene probes will allow detection of somatic tumor-specific amplifications or rearrrangement of genomic loci homologous to these probes. Examination of many tumors of each specific pathologic type may then allow insight into the association of these events with the development of such cancers. Similar evaluations of patients following therapy or in relapse may also provide prognostic information of particular use to the clinical oncologist. The sets of samples of each of the various types will be examined with hybridization probes consisting of segments of genomic human DNA which are homologous to chromosomal loci encompassing polymorphic restriction endonuclease recognition sequences. Comparison of genotypes present in normal and malignant tissues at loci throughout the genome may allow identification of genes whose recessive alleles predispose to specific cancers. (6)
|
0.906 |
1990 |
Cavenee, Webster |
R13Activity Code Description: To support recipient sponsored and directed international, national or regional meetings, conferences and workshops. |
Gordon Conference On Cancer--1990 @ Gordon Research Conferences
The purpose of this application is to request partial support of the travel expenses for invited speakers to the 42nd Gordon Research Conference on Cancer. The conference is entitled "Cancer-Genetics" and will take place August 12-17 at Salve-Regina College in Newport, Rhode Island. The Cancer Conference is the oldest of the Gordon Conferences and has played a unique role in providing a combination of topical research themes and clinical applications. The aim of the 1990 Conference is to consider the development of cancer as a genetically based disease. To this end, it has been organized around an opening lecture followed by none oral sessions and three poster sessions. The oral sessions have been arranged to provide consideration of the genetic aspects of tumor development the following order: 1) Advances in cytogenetic technology and tumor specific alterations; 2) genetics of predisposition to cancer; 3) genetics of tumor progression; 4) genetic mechanisms involved in tumor development; 5) cellular genetics of tumor suppression; 6) epigenetics and genome imprinting in tumorigenesis; 7) oncogenetics and development; 8) genetics of metastasis; and, 9) the clinical significance of genetics alterations in cancer diagnosis. We anticipate selection of about 130 scientists from universities, research institutes, industry and government for participation and each will be asked to present their work orally or in poster session format. We expect that the 1990 Gordon Research Conference on Cancer will provide a lively and pivotal forum for consideration of the genetic basis of cancer, one of the fastest moving and contemporary areas of cancer research.
|
0.928 |
1992 |
Cavenee, Webster |
R13Activity Code Description: To support recipient sponsored and directed international, national or regional meetings, conferences and workshops. |
Conference On Genetics of Cancer @ American Association For Cancer Research
Support is requested for a scientific meeting organized by the American Association for Cancer Research, Inc. (AACR). The conference, entitled "Genetics of Cancer" will be held at the Hilton Head Marriott, Hilton Head, South Carolina, November 4-8, 1992. The Program Organizers for this conference are Drs. Raymond L. White and Webster K. Cavenee. This conference will bring to the attention of both laboratory and clinical scientists the most recent finding on the processes critical to the genetic origin of human malignancies. The invited speakers are well-known investigators in this field. They will make 30-60 minute presentations. Approximately 150-175 other conference registrants will have the opportunity to present their own novel work during poster sessions. The purpose of this conference is to: (1) examine the present state of knowledge of the genes whose defects cause cancer predisposition in families; (2) to evaluate the significance of genetic alterations that occur in the somatic lineages and not in the germline, and; (3) to discuss genetic mechanisms which have been uncovered in other organisms or cell systems and which may play roles in some of the as yet unexplained features of human cancer. We feel that this is an especially appropriate time to pause and take stock of the major achievements of the past few years and to evaluate them in light of novel insights being gathered in the mechanisms of mitosis, genetic stability, cell differentiation, and programmed cell death. This meeting may, then, play a significant role in crystallizing new multidisciplinary approaches to cancer etiology. Participants will be drawn from a variety of scientific areas and all levels of training from graduate students to senior basic scientists or clinical investigators. It is therefore anticipated that the conference will result in a fruitful exchange of information that will enrich current research and suggest new conceptual insights into the genesis and propagation of the neoplastic state.
|
0.948 |
2008 — 2012 |
Cavenee, Webster |
P01Activity Code Description: For the support of a broadly based, multidisciplinary, often long-term research program which has a specific major objective or a basic theme. A program project generally involves the organized efforts of relatively large groups, members of which are conducting research projects designed to elucidate the various aspects or components of this objective. Each research project is usually under the leadership of an established investigator. The grant can provide support for certain basic resources used by these groups in the program, including clinical components, the sharing of which facilitates the total research effort. A program project is directed toward a range of problems having a central research focus, in contrast to the usually narrower thrust of the traditional research project. Each project supported through this mechanism should contribute or be directly related to the common theme of the total research effort. These scientifically meritorious projects should demonstrate an essential element of unity and interdependence, i.e., a system of research activities and projects directed toward a well-defined research program goal. |
Resistance to Therapeutics Directed At the Egfr/Pi3-K Pathways in Glioblastoma @ Dana-Farber Cancer Institute
4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy]; AKT; Acetylation; Address; Akt protein; Anchorage-Independent Growth; Antibodies; Apoptosis; Apoptosis Pathway; Assay; Astrocytes; Astrocytoma, Grade IV; Astrocytus; Astroglia; BZS; Behavior; Bio-Informatics; Bioassay; Bioinformatics; Biologic Assays; Biological; Biological Assay; Bypass; Cancer Genes; Cancer Radiotherapy; Cancer-Promoting Gene; Candidate Disease Gene; Candidate Gene; Catalytic Core; Catalytic Domain; Catalytic Region; Catalytic Site; Catalytic Subunit; Cell Communication and Signaling; Cell Cycle; Cell Death, Programmed; Cell Division Cycle; Cell Line; Cell Lines, Strains; Cell Signaling; Cell/Tissue, Immunohistochemistry; CellLine; Cells; Chickens; Chromosome Mapping; Clinical; Clinical Research; Clinical Study; Clinical Trials; Clinical Trials, Unspecified; Collaborations; Collection; Colony-Forming Units, Neoplastic; Complement; Complement Proteins; Condition; Data; Data Set; Dataset; Deep; Depth; Disease Progression; Dosage Compensation; Dosage Compensation (Genetics); Drug resistance; EGF; EGF gene; EGFR; EGFR Blocker; EGFR Inhibitor; EGFR Tyrosine Kinase Inhibitor; EGFR-TK Inhibitor; ERBB Protein; ERBB1; Effectiveness; Embryo; Embryonic; Engineering; Engineerings; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Inhibitor; Epidermal Growth Factor Receptor Kinase; Epidermal Growth Factor Receptor Protein-Tyrosine Kinase; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; FLR; Failure (biologic function); Fibroblasts; Fostering; Funding; GFAC; Gallus domesticus; Gallus gallus; Gallus gallus domesticus; Gefitinib; Gene Action Regulation; Gene Chips; Gene Expression; Gene Expression Chip; Gene Expression Regulation; Gene Localization; Gene Mapping; Gene Mapping, Total Human and Non-Human; Gene Products, RNA; Gene Regulation; Gene Regulation Process; Gene Transfer Techniques; Generalized Growth; Genes; Genetic; Genetic Alteration; Genetic Change; Genetic Screening; Genetic defect; Genetics, Gene Mapping; Genetics, in situ Hybridization; Genomics; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Glioblastoma; Glioma; Gliomagenesis; Goals; Grade IV Astrocytic Neoplasm; Grade IV Astrocytic Tumor; Growth; Growth Agents; Growth Factor; Growth Factors, Proteins; Growth Substances; HER1; Human; Human, General; IHC; Immunohistochemistry; Immunohistochemistry Staining Method; In Situ Hybridization; Institutes; Intracellular Communication and Signaling; Investigation; Iressa; Knock-in; Knock-in Mouse; Knowledge; Lead; Lesion; Letters; Linkage Mapping; Localized; MHAM; MMAC1; MMAC1 protein; Maintenance; Maintenances; Mammals, Mice; Man (Taxonomy); Man, Modern; Maps; Measures; Mediating; Mice; Modeling; Mother Cells; Murine; Mus; Mutate; Mutation; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; Nature; Neoplasms of Neuroglia; Neural Stem Cell; Neuroglial Neoplasm; Neuroglial Tumor; Oncogenes; Overexpression; P/CAF; PCAF; PCAF gene; PKB protein; PTEN; PTEN gene; PTEN protein; PTEN1; Pathogenesis; Pathway interactions; Patients; Pb element; Phenotype; Phosphatase and Tensin Homolog; Post-Transcriptional Gene Silencing; Post-Transcriptional Gene Silencings; Post-Translational Modifications; Post-Translational Protein Processing; Posttranscriptional Gene Silencing; Posttranscriptional Gene Silencings; Posttranslational Modifications; Principal Investigator; Progenitor Cells; Programs (PT); Programs [Publication Type]; Property; Property, LOINC Axis 2; Protein Kinase B; Protein Modification; Protein Modification, Post-Translational; Protein Overexpression; Protein Processing, Post-Translational; Protein Processing, Posttranslational; Protein/Amino Acid Biochemistry, Post-Translational Modification; Proteins; Proteomics; Proto-Oncogene Proteins c-akt; Quelling; RAC-PK protein; RNA; RNA Interference; RNA Silencing; RNA Silencings; RNA, Non-Polyadenylated; RNAi; Radiation therapy; Radiotherapeutics; Radiotherapy; Receptor Protein; Receptor Signaling; Receptor, EGF; Receptor, TGF-alpha; Receptor, Urogastrone; Receptors, Epidermal Growth Factor-Urogastrone; Recurrence; Recurrent; Research Institute; Research Specimen; Resistance; Ribonucleic Acid; Role; S cerevisiae; SEQ-AN; Saccharomyces cerevisiae; Sampling; Science of neurosurgery; Sequence Analyses; Sequence Analysis; Sequence-Specific Posttranscriptional Gene Silencing; Signal Pathway; Signal Transduction; Signal Transduction Systems; Signaling; Signaling Molecule; Specificity; Specimen; Standards; Standards of Weights and Measures; Stem Cells, Neoplastic; Stem cells; System; System, LOINC Axis 4; Tarceva; Target Populations; Technology; Testing; Therapeutic; Time; Tissue Arrays; Tissue Chip; Tissue Growth; Tissue Microarray; Transforming Genes; Transforming Growth Factor alpha Receptor; Transgenesis; Transgenic Organisms; Triage; Tumor Stem Cells; Tumors of Neuroglia; URG; Validation; Yeast, Baker's; Yeast, Brewer's; Yeasts; attenuation; base; biological signal transduction; c-akt protein; c-erbB-1; c-erbB-1 Protein; cDNA Library; cell transformation; clinical investigation; clinical relevance; clinically relevant; cultured cell line; drug resistant; erbB-1; erbB-1 Proto-Oncogene Protein; erbBl; experiment; experimental research; experimental study; expression vector; failure; falls; gene product; genetic mapping; genome mutation; glioblastoma multiforme; glioma genesis; heavy metal Pb; heavy metal lead; in situ Hybridization Staining Method; in vivo; inhibitor; inhibitor/antagonist; irradiation; knock-down; member; migration; mutant; mutated in multiple advanced cancers 1 protein; nerve stem cell; neural progenitor cells; neuronal progenitor; neuronal progenitor cells; neuropathology; neurosurgery; novel; ontogeny; overexpress; pathway; phosphatase and tensin homologue on chromosome ten; pre-clinical; preclinical; programs; protein-serine-threonine kinase (rac); proto-oncogene protein RAC; proto-oncogene protein akt; proto-oncogene protein c-erbB-1; rac protein kinase; receptor; receptor expression; receptor function; related to A and C-protein; research study; resistance mechanism; resistance to Drug; resistance to therapy; resistant; resistant mechanism; resistant to Drug; resistant to therapy; response; shRNA; short hairpin RNA; small hairpin RNA; small molecule; social role; spongioblastoma multiforme; stem; therapeutic target; therapy resistant; transformed cells; transgenic; tumor; tumorigenic; yeast genetics
|
0.96 |